Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast Cancer

Autor: Hans-Joachim Lück, G. W. Sledge, John R. Mackey, Laura Biganzoli, Martine J. Piccart-Gebhart, Patrick Therasse, Gul Basaran, S Chan, James Carmichael, M. Bontenbal, Robert Paridaens, Jacek Jassem, Jean-Marc Nabholtz, Marc Buyse, J. Bonneterre, Tomasz Burzykowski

Publikováno v: Journal of Clinical Oncology, 26(12), 1987-1992. AMER SOC CLINICAL ONCOLOGY
Journal of Clinical Oncology, 26(12), 1987-1992. American Society of Clinical Oncology

Purpose Overall survival (OS) can be observed only after prolonged follow-up, and any potential effect of first-line therapies on OS may be confounded by the effects of subsequent therapy. We investigated whether tumor response, disease control, prog

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ea0ef331e173756a44d779ac6f6680d
https://doi.org/10.1200/jco.2007.10.8407

Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial

Autor: S. Edgerton, W. J. Gradishar, D. Murrey, Karen L. Tedesco, Douglas E. Merkel, L. J. Goldstein, K. A. Blum, Ann D. Thor, Yu Shyr, David H. Johnson, G. W. Sledge, Brenda P. Nicholson

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 22(6)

Purpose To determine the efficacy and safety of weekly docetaxel and trastuzumab as first- or second-line therapy in women with HER-2–overexpressing metastatic breast cancer and to correlate the efficacy of trastuzumab with HER-2 status as determin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ec9ed0d06d6400c0b7b7e9ac6b01589
https://pubmed.ncbi.nlm.nih.gov/15020608

Exploiting the hallmarks of cancer: the future conquest of breast cancer

Autor: G W, Sledge, K D, Miller

Publikováno v: European journal of cancer (Oxford, England : 1990). 39(12)

What separates a malignant from a normal cell? This question has occupied scientists for decades. Although a simple answer remains elusive, several hallmarks of malignancy have been identified. These critical features include uncontrolled proliferati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::2626a42c980b99320b074dc04429fa32
https://pubmed.ncbi.nlm.nih.gov/12888360

P5-06-01: Gene Expression Analysis of Resistance to Bevacizumab in a VEGF-Reinforced Xenograft Model of ER-Positive Breast Cancer

Autor: Changyu Shen, Rachel A. Toroni, Kerry L. Sanders, Chirayu Goswami, Rutika Mehta, Yesim Gökmen-Polar, G. W. Sledge, Sunil Badve, Usha Sirimalle, Mircea Ivan, Lang Li, Bogdan Tanasa

Publikováno v: Cancer Research. 71:P5-06

Background: Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), had promising therapeutic efficacy in breast cancer. However, intrinsic or acquired resistance is common in the clinic. To improve our understanding o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a2345f6eca9e659d3eecf9cb6b3f6a35
https://doi.org/10.1158/0008-5472.sabcs11-p5-06-01

The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors

Autor: C J, Sweeney, K D, Miller, S E, Sissons, S, Nozaki, D K, Heilman, J, Shen, G W, Sledge

Publikováno v: Cancer research. 61(8)

Numerous chemotherapeutic agents have been shown to have an inhibitory effect on endothelial cell proliferation and migration, and tubule formation. In this study, we examined the antiangiogenic activity of docetaxel. Docetaxel inhibited endothelial

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::60afebdd3adcbfb5d96ff5d11b3eee97
https://pubmed.ncbi.nlm.nih.gov/11309294